Custom Pharma Services
Nigel Richardson has over 43 years of experience at Custom Pharma Services, including serving as Chairman since June 2002 and previously as CEO, where significant growth and development took place under their leadership. As CEO, Nigel propelled Custom Pharmaceuticals Ltd from its startup phase in 1979, fostering a committed team and overseeing a major investment of approximately £20 million into new facilities focused on high potency formulation capabilities. Prior to this role, Nigel held the position of Managing Director at Custom Pharmaceuticals Ltd from 1984 to 2002. Nigel's academic background includes a BSc in Urban Land Administration from Portsmouth Polytechnic, complemented by education at various institutions including East Grinstead County Grammar and Reading Bluecoat School.
This person is not in the org chart
This person is not in any teams
Custom Pharma Services
1 followers
Custom Pharma Services is located in Brighton, UK since 1979 and is a full-service contract development and manufacturing organisation (CDMO) providing services tailored to your needs, no matter how niche or complex. Custom covers the full spectrum of activities from development through commercial manufacturing for both clinical and commercial use. Specialising in Oral Solid Dosage forms with the ability to handle highly potent drugs and poorly bioavailable compounds Custom really is your one stop resource. With direct access to highly skilled experts offering a partnership approach Custom Pharma Services truly has a molecule first mentality, managing all projects with the end in mind. Custom Can! • Custom Pharma is a CDMO offering clinical and commercial manufacturing of tablets, capsules, powders (oral-solid-dose) for human use. • Services comprise pre-formulation and formulation development, analytical development, stability testing, clinical trial material manufacturing • Commercial Production • Pre-clinical formulation development and solubilisation • Material characterisation • Drug in capsule approach to accelerate early clinical studies • Specialists in low dosage (sub-mg) formulations • Contained manufacturing for highly potent APIs • Orphan drug development • Formulation development of poorly soluble drugs, including spray drying capabilities